Medical/Pharmaceuticals
Program CD47, provided the CMC service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp
NEW YORK and LONDON, Dec. 5, 2022 /PRNewswire/ -- Recently, Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") (Nasdaq: IRAA), a publicly traded special purpose acquisition company ...
2022-12-05 20:00
1821
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
HANGZHOU, China, Dec. 5, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has dosed the first patient in a Phase II clinical trial of its innovative drug LNK01003 in Ulcerative Colitis ...
2022-12-05 08:00
2601
Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353)
ROCKVILLE, Md. and SUZHOU, China, Dec. 5, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2022-12-05 08:00
3067
Telix Announces Executive Leadership Appointments
MELBOURNE, Australia, Dec. 5, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning. Richard Valei...
2022-12-05 06:39
2009
FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) ANNOUNCES $5 MILLION GIFT TO ADVANCE CLINICAL TRIALS IN RARE NEURODEVELOPMENTAL DISORDERS
The Center at Rush University Will Be Directed By Dr. Elizabeth Berry-Kravis MIAMI, Dec. 3, 2022 /PRNewswire/ -- The Foundation for Angelman Syndrome Therapeutics (FAST) announced today a$5 million gift to establish the new clinical trial and translational research effort for rare neurodevelopmen...
2022-12-03 01:07
3425
Epiprotect reduces the cost for treatment of hard to heal leg ulcers with 83%
LINKÖPING, Sweden, Dec. 3, 2022 /PRNewswire/ -- A compilation of data from patients treated at S2Clinic during the period 2019-2022 showed that the cost of treatment of these patients was reduced by approximately 83% compared to conventional treatment. The treatment with Epiprotect also resulted ...
2022-12-03 00:41
3039
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
CEO Lance Kawaguchi Drives Effort & Brings Compelling Personal Story to Global Battle Against Cancer NEW YORK, Dec. 3, 2022 /PRNewswire/ -- Cure Brain Cancer Foundation CEO Lance Kawaguchi rang the bell to open trading on the Nasdaq stock exchange on Friday morning,December 2. The Foundation ann...
2022-12-02 23:00
3162
Sirolimus Coated Balloon in BTK Treatment makes a bold presence at VEITH 2022 - Lights up NY Times Square, NASDAQ
TAMPA, Fla., Dec. 2, 2022 /PRNewswire/ -- VEITH 2022 witnessed a surge of
supporting clinical data for Sirolimus Coated Balloon in the treatment of
Below-the-Knee (BTK) disease.Concept Medical Inc
2022-12-02 21:10
3750
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
JERSEY CITY, N.J. and SHANGHAI, Dec. 2, 2022 /PRNewswire/ -- Focus-X Therapeutics (referred to here as "Focus-X"), a nuclide drug company that was invested in and incubated by Viva Biotech, successfully reached an acquisition agreement with Full-Life Technologies Co., Ltd. (referred to here as "...
2022-12-02 18:23
3765
Parnell Pharmaceuticals Holdings Ltd Announces Proposed Rights Offering
SYDNEY, Dec. 2, 2022 /PRNewswire/ -- Parnell Pharmaceuticals Holdings Ltd (OTC Pink® Open Market: PARNF) ("Parnell") announced its intention to raise US$4.0 million through a backstopped rights offering at no charge (the "Rights Offering") for qualifying shareholders of record as ofDecember 6, 20...
2022-12-02 10:05
3941
Innoforce Opens GMP Manufacturing Facility & Corporate Headquarters in Hangzhou, China to Provide CDMO Services for Global Supply of RNA, Cell & Gene Therapies
The new site adds to its capacity in China & US to provide end-to-end process development and global manufacturing services for advanced therapies HANGZHOU, China, Dec. 2, 2022 /PRNewswire/ -- Innoforce, a global provider of end-to-end contract development and manufacturing services (CDMO), today...
2022-12-02 06:00
2467
Armis Named Clear Leader in SPARK Matrix for Connected Medical Device Security Solutions
Company recognized for comprehensive and robust asset intelligence platform; ranked highest among competitors for technology excellence and customer impact SAN FRANCISCO, Dec. 1, 2022 /PRNewswire/ -- Armis, the leading asset visibility and security company, today announced that it has been named ...
2022-12-01 22:50
2140
HAVAS HEALTH & YOU EXPANDS CONTENT EXPERTISE THROUGH PARTNERSHIP WITH EVERMED
NEW YORK, Dec. 1, 2022 /PRNewswire/ -- COVID-19 dramatically changed the way doctors interact with the health industry – they're looking for more convenient and efficient ways to consume medical information than ever, leading to an uptick in demand for content. To help address the need for more c...
2022-12-01 22:15
2122
Creating the Leaders of Tomorrow: The Valuable 500 Reach Milestone for 'Generation Valuable' on International Day for Persons with Disabilities
* Powered by Verizon, the Valuable 500 has enlisted 75 Generation Valuable Mentees and Mentors * Launching in January 2023, the Generation Valuable participants will gain access to world-class creative leadership courses and collaborative opportunities with the other multinational corporation...
2022-12-01 21:27
1473
BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine
VANCOUVER, BC, Dec. 1, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce the successful sterile and bacteria-free test-run production of BVX-0918, the Company's bi-haptenized autologous ovarian cancer vaccine. ...
2022-12-01 21:00
3368
Encore Medical Education announces publication of the Official Best of SABCS® News Highlights summarizing key trial results from the 2022 SABCS®
Best of SABCS® News Highlights coverage will provide daily expert video
summaries along with original presentation slides of the most significant
breast cancer trials for oncologists worldwide.
SAN ANTONIO, Dec. 1, 2022 /PRNewswire/ -- Encore Medical Education,
2022-12-01 15:15
1934
LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development
- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday,30th November 2022,...
2022-12-01 03:45
1775
Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS) that Demonstrate Elacestrant's PFS Increases with Duration of Prior CDK4/6i in ER+, HER2- in Metastatic Setting
* Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors * Elacestrant side effects were manageable and consistent with previously reported result...
2022-12-01 00:56
1932
Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index
LONDON and HONG KONG, Nov. 30, 2022 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced that its board of directors has authorized a share repurchase program, and that it has been included as a c...
2022-11-30 22:15
3121
Kira Pharmaceuticals Announces First Cohort of Patients Dosed in Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
CAMBRIDGE, Mass., Nov. 30, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced that the first cohort has been dosed in a Phase 2 trial evaluating KP104 for the treatment of pa...
2022-11-30 20:00
1619
Week's Top Stories
Most Reposted
Agoda and TPB Philippines join hands to bring the world to the Philippines' shores
[Picked up by 350 media titles]
2024-09-18 11:30
FETC International's MD Dr. Y.C. Chang Honored with the "Master Entrepreneur Award" at APEA 2024
[Picked up by 315 media titles]
2024-09-16 11:50
Mox Capital Announces Strategic Support for Rapid-Scaling Startups Across Vietnam and Southeast Asia
[Picked up by 284 media titles]
2024-09-14 17:37
Illumina and LGC Biosearch Technologies join forces to drive genomic innovation in agriculture
[Picked up by 283 media titles]
2024-09-19 14:00
Watsons-Marlow unveils Qdos™ H-FLO and WMArchitectTM :Innovating fluid solutions for the chemical and biopharmaceutical industries respectively
[Picked up by 274 media titles]
2024-09-19 08:00
Most Read
Mox Capital Announces Strategic Support for Rapid-Scaling Startups Across Vietnam and Southeast Asia
2024-09-14 17:37
9772
Maiji Mountain Grottoes: Carved in stone, evolving in time
2024-09-14 13:23
8197
FETC International's MD Dr. Y.C. Chang Honored with the "Master Entrepreneur Award" at APEA 2024
2024-09-16 11:50
8120
Vision China: US, China urged to find right path in ties
2024-09-14 01:10
7681
Agoda and TPB Philippines join hands to bring the world to the Philippines' shores
2024-09-18 11:30
6228